Gene Therapy for Relapsed and Refractory Multiple Myeloma is under clinical development by Guangzhou Bio-gene Technology and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy for Relapsed and Refractory Multiple Myeloma’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy for Relapsed and Refractory Multiple Myeloma overview
Gene therapy is under development for the treatment of relapsed and refractory acute myeloid leukemia. The therapeutic candidate comprises of T-cells genetically modified to express chimeric antigen receptor (CAR). It acts by targeting CD33, CD123 and CLL1 surface antigens. It is administered through parenteral route.
For a complete picture of Gene Therapy for Relapsed and Refractory Multiple Myeloma’s drug-specific PTSR and LoA scores, buy the report here.